Estimating background rates of Guillain-Barr-Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign

Deeks, Shelley L.; Lim, Gillian H.; Simpson, Mary Anne; Rosella, Laura; Mackie, Christopher O.; Achonu, Camille; Crowcroft, Natasha S.
January 2011
BMC Public Health;2011 Supplement 4, Vol. 11 Issue Suppl 4, p329
Academic Journal
Background: The province of Ontario, Canada initiated mass immunization clinics with adjuvanted pandemic H1N1 influenza vaccine in October 2009. Due to the scale of the campaign, temporal associations with Guillain- Barré syndrome (GBS) and vaccination were expected. The objectives of this analysis were to estimate the number of background GBS cases expected to occur in the projected vaccinated population and to estimate the number of additional GBS cases which would be expected if an association with vaccination existed. The number of influenza-associated GBS cases was also determined. Methods: Baseline incidence rates of GBS were determined from published Canadian studies and applied to projected vaccine coverage data to estimate the expected number of GBS cases in the vaccinated population. Assuming an association with vaccine existed, the number of additional cases of GBS expected was determined by applying the rates observed during the 1976 Swine Flu and 1992/1994 seasonal influenza campaigns in the United States. The number of influenza-associated GBS cases expected to occur during the vaccination campaign was determined based on risk estimates of GBS after influenza infection and provincial influenza infection rates using a combination of laboratory-confirmed cases and data from a seroprevalence study. Results: The overall provincial vaccine coverage was estimated to be between 32% and 38%. Assuming 38% coverage, between 6 and 13 background cases of GBS were expected within this projected vaccinated cohort (assuming 32% coverage yielded between 5-11 background cases). An additional 6 or 42 cases would be expected if an association between GBS and influenza vaccine was observed (assuming 32% coverage yielded 5 or 35 additional cases); while up to 31 influenza-associated GBS cases could be expected to occur. In comparison, during the same period, only 7 cases of GBS were reported among vaccinated persons. Conclusions: Our analyses do not suggest an increased number of GBS cases due to the vaccine. Awareness of expected rates of GBS is crucial when assessing adverse events following influenza immunization. Furthermore, since individuals with influenza infection are also at risk of developing GBS, they must be considered in such analyses, particularly if the vaccine campaign and disease are occurring concurrently.


Related Articles

  • Small risk of Guillain-Barré syndrome with H1N1 2009 vaccines.  // Reactions Weekly;03/23/2013, Issue 1445, p2 

    The article reports that according to the results of a large meta-analysis in the U.S., influenza A (H1N1) 2009 monovalent inactivated vaccines contributed in slightly increasing the risk of Guillain-Barr'e syndrome (GBS).

  • HIN1 vaccine given to pregnant women not linked to GBS, poor birth outcomes.  // Infectious Disease News;Aug2012, Vol. 25 Issue 8, p28 

    The article discusses the two separate studies that contrasts findings regarding the safety of influenza A(H1N1) vaccine given to pregnant women and risk of Guillain-Barré syndrome (GBS) among adults.

  • Slight risk for Guillain-Barré syndrome attributed to HIN1 vaccine.  // Infectious Disease News;Apr2013, Vol. 26 Issue 4, p25 

    The article discusses the results of a study conducted by Dr. Bruce Gellin and colleagues and published in the "Lancet" journal regarding the association between the development of Guillain-Barré syndrome and the administration of influenza A (H1N1) 2009 monovalent inactivated vaccine.

  • H1N1 immunisation: too much too soon? COLLIGNON, PETER // Natural Health & Vegetarian Life;Winter2010, p34 

    In this article, the author comments on the risks and adverse effects of H1N1 vaccination prompted by the swine flu outbreak in Australia in the winter of 2009. It discusses the findings of an Australian H1N1 vaccine trial of adults indicating that more than half of the Australian population are...

  • H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Farez, Mauricio F; Ysrraelit, Mar�a C; Fiol, Marcela; Correale, Jorge // Multiple Sclerosis Journal;Feb2012, Vol. 18 Issue 2, p254 

    The article discusses the study on the effects of the H1N1 influenza vaccines in patients with multiple sclerosis (MS). It states that there was no association between H1N1 immunization and increased exacerbation rate in MS which was the conclusion of the study. It discusses H1N1 influenza...

  • Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands. van Puijenbroek, Eugène P.; Broos, Nancy; van Grootheest, Kees // Drug Safety;2010, Vol. 33 Issue 12, p1097 

    Background: In November 2009, a vaccination campaign against Influenza A (H1N1) was started in the Netherlands. The accelerated registration procedure of the vaccines used in this campaign and the use of these vaccines on a large scale indicated a need for real-time safety monitoring. Objective:...

  • The Safety of H1N1 Vaccine in Children in Saudi Arabia: A Cohort Study Using Modem Technology in a Developing Country. Aljadhey, Hisham; Alyabsi, Mesnad; Alrwisan, Adel; Alqahtani, Nasser; Almutairi, Reem; Al Tawil, Esraa; Adam, Mansour; Shakir, Saad; Aljeraisy, Majed; Al-Blowi, Ali; Alkhashan, Hesham; Albogami, Yasser; Murray, Michael D. // Drug Safety;2012, Vol. 35 Issue 7, p555 

    Background: With its rapid introduction in 2009, concerns about the safety of the H1N1 vaccines have been raised. Data were especially limited on the pediatric safety of H1N1 vaccine in Saudi Arabia. Objectives: The objectives of this study were to investigate the safety of the H1N1 vaccine...

  • Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials. Mallory, Raburn M.; Malkin, Elissa; Ambrose, Christopher S.; Bellamy, Terramika; Shi, Li; Yi, Tingting; Jones, Taff; Kemble, George; Dubovsky, Filip // PLoS Clinical Trials;Oct2010, Vol. 7 Issue 10, Special section p1 

    Background: The safety, tolerability, and immunogenicity of a monovalent intranasal 2009 A/H1N1 live attenuated influenza vaccine (LAIV) were evaluated in children and adults. Methods/Principal Findings: Two randomized, double-blind, placebo-controlled studies were completed in children (2-17 y)...

  • Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. Openshaw, P J M; Dunning, J // Mucosal Immunology (1933-0219);Sep2010, Vol. 3 Issue 5, p422 

    In this article the authors discuss the lessons that they have learned during the outbreak of the pandemic (H1N1) influenza virus on 2009. The authors discover that the virus is only a mild infection which brought severe diseases to people due to the combination of host genotype and the virus...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics